AstraZeneca COPD drug shows trial success, sales forecast raised
New data on tozorakimab suggests it could significantly reduce flare-ups in patients with chronic obstructive pulmonary disease.
AI-assisted coverage comparison, editor-supervised · How this was made
AstraZeneca COPD drug shows trial success, sales forecast raised
Photograph: CNBC (embedded from source)
What this story says
- AstraZeneca's experimental drug tozorakimab has shown success in two late-stage trials for chronic obstructive pulmonary disease (COPD).
- The drug reduced moderate to severe COPD flare-ups by 23% to 43% in different patient groups compared to a placebo.
- AstraZeneca has increased its projected peak annual sales for tozorakimab to more than $5 billion.
- US approval for the drug is anticipated in the first quarter of 2027, with the FDA currently reviewing it.
Who covered it
Percentages are shares of the 4 outlets carrying a published leaning rating. 1 of the 5 outlets we know ran this story carry no rating and are not counted in them. Coverage measured .
Trust
60/100
Craft
65/100
Hype
41/100
5 sources · methodology
AstraZeneca has published the full results from two successful late-stage clinical trials for its experimental drug, tozorakimab, intended for the treatment of chronic obstructive pulmonary disease (COPD). The drug, which targets the protein IL-33 that drives inflammation and mucus production, demonstrated a reduction in moderate and severe COPD flare-ups across various patient subsets. These results have bolstered the company's sales expectations for the drug.
In the trials, tozorakimab helped reduce moderate and severe flare-ups by between 23% and 43% when compared to a placebo, depending on the patient group. The company reported that the drug reduced flare-ups by 29% and 34% in former smokers with moderate and severe conditions, respectively. In a broader population of current and former smokers, reductions were 30% and 29%.
The drug is currently under priority review by the US Food and Drug Administration, with an expected approval in the first quarter of 2027. AstraZeneca has raised its forecast for the drug's peak annual sales to more than $5 billion, contributing to its broader revenue target of $80 billion by 2030. The company believes tozorakimab has the potential to reach a large number of COPD patients who are currently underserved by existing biologic treatments.
Disagreement on specific reduction figures
Reports differ on the exact percentage reductions in flare-ups. CNBC reported that the drug reduced moderate and severe flare-ups by 23% in patients with a blood eosinophil count below 150, by 34% in those with a count at or above 150, and by 43% in those at or above 300. The verified claims stated that the drug helped reduce moderate and severe COPD flare-ups by 23% to 43% in various patient subsets compared to placebo.
What the coverage left out
None of the left-rated reports mention the specific figures for the reduction in moderate and severe flare-ups in former smokers, which were reported as 29% and 34% respectively. The left-rated reports also do not detail the specific figures for the reduction in moderate and severe flare-ups in the larger overall population of current and former smokers, which were 30% and 29% respectively.
Still developing. We have re-checked which outlets are covering this 3 times, most recently on 8 Sept 2026, 12:45, and will add the sides that appear.
How each side covered it
Our own reading of the reporting listed below, written from the outlets’ articles rather than quoted from them. The reasoning is set out on our methodology page.
Left
1 rated outlet
- The left-rated report from CNBC highlighted the successful late-stage trial results for AstraZeneca's COPD drug, tozorakimab, and the company's increased sales forecast. It detailed the drug's mechanism of action, blocking the IL-33 protein to reduce inflammation and mucus production. The report included quotes from AstraZeneca executives, including CEO Pascal Soriot, discussing the drug's potential to capture a broad patient group due to significant unmet need and underuse of biologics in COPD compared to asthma. It also noted the drug's performance across different patient groups, including those with low eosinophil counts, for whom current biologic treatments are limited. The article mentioned the drug is under FDA priority review with an expected US approval in early 2027.
Centre
3 rated outlets
- All three centre‑rated outlets reported that AstraZeneca’s experimental COPD medicine, referred to as Tozo or Tozorakimab, achieved a reduction in disease flare‑ups in late‑stage trials. The digests note statistically significant and clinically meaningful benefits across a broad patient population, and that the results were published in a leading medical journal and presented at a European conference.
- Bloomberg’s digest highlighted the drug’s impact on flare‑up rates and its potential as a blockbuster product. Market Screener’s summary specified the OBERON and TITANIA Phase III studies, emphasized the statistical significance of the exacerbation reduction and noted benefit across blood eosinophil levels. STAT’s brief pointed to the treatment’s competitiveness with other emerging COPD therapies and its capacity to reach a larger patient base.
- None of the centre digests included any information on the drug’s projected price, sales forecast, regulatory approval timeline, or patient‑access programmes. They also did not quote external clinicians, industry analysts, or patient organisations, leaving those perspectives absent from the coverage.
Right
0 rated outlets
No outlet rated right has run this story so far. We are still checking, and will say plainly if that does not change.
Questions about this coverage
- How did the left and right cover AstraZeneca COPD drug shows trial success, sales forecast raised?
- Of the 4 outlets on this story carrying a published leaning rating, 25% are rated left, 75% are rated centre, 0% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it, which was 5. The sections above set out what each side emphasised, in its own terms.
- Is AstraZeneca COPD drug shows trial success, sales forecast raised left or right?
- Too few of the outlets on this story carry a published leaning rating to say. 4 of them do, and this site does not characterise a field under 12: at that size one newsroom filing moves the share by ten points. The percentages above are the count as it stands.
- Is the coverage of AstraZeneca COPD drug shows trial success, sales forecast raised biased?
- AstraZeneca COPD drug shows trial success, sales forecast raised is one event reported by 5 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.
- Which outlets covered AstraZeneca COPD drug shows trial success, sales forecast raised?
- 5 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.
- What is tozorakimab and what does it do?
- Tozorakimab is an experimental drug developed by AstraZeneca for chronic obstructive pulmonary disease (COPD). It works by blocking a protein called IL-33, which is known to drive inflammation and mucus production in the airways, aiming to reduce the frequency and severity of COPD flare-ups.
- How effective were the trial results for tozorakimab?
- In late-stage trials, tozorakimab reduced moderate and severe COPD flare-ups by 23% to 43% in various patient groups compared to a placebo. These results have increased confidence in the drug's potential as a significant treatment for the condition.
- What is AstraZeneca's sales forecast for tozorakimab?
- Following the positive trial results, AstraZeneca has raised its peak annual sales forecast for tozorakimab to more than $5 billion. This projection contributes to the company's overall revenue goals and highlights the perceived market potential for the drug.
- When might tozorakimab be approved in the US?
- The drug is currently under priority review by the US Food and Drug Administration. AstraZeneca anticipates that US approval for tozorakimab could be granted in the first quarter of 2027.
Read it at the source
5 outlets, grouped by the leaning a published rating gives them. Every headline links to the original; an underlined outlet name opens our profile of that publisher.
Left
1Centre
3- AstraZeneca’s Lung Disease Drug Shows Broad Benefit in Trials (opens Bloomberg in a new tab)
- AstraZeneca : Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials (opens Market Screener in a new tab)
Market Screener — is Market Screener biased? Our profile of this outlet
- AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies (opens STAT in a new tab)
Right
0No outlet in this group ran the story.
Not rated
1How did this read?
About the coverage, not about the story. We do not ask whether you agree with what happened — we have no honest use for that answer.
More in Health
All Health →
Elsewhere on the site
Conflict & Security•4 min readUS Officials Discuss Reducing Middle East Presence
Conflict & Security•2 min readUK to test reserve mobilisation in military exercise next year
Politics•2 min readSaskatchewan Imposes 50% Tax on American Alcohol
Business & Economy•3 min readHouthis attack Saudi energy sites, wounding 73; oil prices surge